Actio Biosciences
Developing precision medicine through genetics for rare and common diseases, streamlining drug discovery and development.
Founded
2021Developing precision medicine through genetics for rare and common diseases, streamlining drug discovery and development.
Founded with a mission to revolutionize precision medicine, Actio Biosciences focuses on developing therapeutics that target the shared underlying biology of both rare and common diseases. Leveraging advances in genetics, drug discovery, and data sciences, the company aims to streamline the drug development process and bring forward potent, precisely targeted treatments. Actio Biosciences is dedicated to identifying programs where biological and technical risks can be minimized, ensuring the efficient development of meaningful medicines.
Actio Biosciences boasts a team of experts in genetics and drug discovery, supported by notable investors committed to advancing precision medicine. The company's innovative approach has led to significant achievements in identifying promising therapeutic targets that address high unmet medical needs. By bridging the gap between rare and common diseases, Actio Biosciences is making a substantial impact on the healthcare landscape, offering new hope for patients through its cutting-edge treatments.
Companies similar to Actio Biosciences include Empirico, Variant Bio, Cogent Biosciences and Judo Bio.
Actio Biosciences was founded in 2021.
Actio Biosciences' headquarters is located in San Diego, CA, US.
Actio Biosciences' most recent funding round was for $66M (USD) in June 2025.
As of Jun 1, 2025, Actio Biosciences has disclosed funding of $121M (USD). Undisclosed round amounts are excluded.
Actio Biosciences has 22 employees as of Feb 4, 2024.
Judo Bio
